A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

NCT04948697 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: Ociperlimab
DRUG: Tislelizumab
DRUG: BAT1706

Sponsor

BeiGene